A Pilot Study To Examine The Effects Of Ticagrelor To Protect Against Type 2 Diabetes-Induced Vascular Damage

NCT ID: NCT02214654

Last Updated: 2014-08-12

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 144 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2014-08-31
• Study Completion Date: 2015-06-30

Brief Summary

The purpose of this study is to compare clopidogrel with ticagrelor which one has stronger anti-inflammation effect to protect against type 2 diabetes-induced vascular damage.

Detailed Description

i- Verify the study inclusion and exclusion criteria at visit 1.

ii- Inform patients (verbally and in writing) and their caregivers (when considered necessary and with the patient's consent) of the characteristics of the study and confirm their agreement to participate by signing the informed consent document.

iii- Assist with patient assessment, record the information in the case report form. Based on the data we get from the case report form, assign the patient to the experimental or control group by stratified randomization.

ⅳ- At visit 2 to obtain blood sample from peripheral vessel and analyze the density of CECs,sCD40L and hs-CRP by flow cytometry (FCM), ELISA and particle-enhanced turbidimetric immunoassay.

ⅴ- All patients are given aspirin 100mg/qd orally and the experimental group given ticagrelor 90mg/bid while the control group clopidogrel 75mg/qd for 30 days.

ⅵ- At visit 3 repeating step ⅳ and making comparison on numbers of CECs and CD40L between the two groups, and finish a statistic analysis.

Conditions

Type 2 Diabetes Mellitus； Stable Coronary Disease

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: PROSPECTIVE

Study Groups

ticagrelor，clopidogrel，antiplatelet drugs

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

1. Provision of informed consent prior to any study specific procedures.

2. A previous or new diagnosis of type 2 diabetes mellitus, document by one of following criteria:1）Hemoglobin A1c of ≥6.5% at diagnosis;2) Fasting plasma glucose (FPG) ≥126mg/dL (7.0 mmol/L);3) Two-hour plasma glucose≥200 mg/dL (11.1 mmol/L) during an oral glucose tolerance test (OGTT);4) with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose≥200mg/dL (11.1 mmol/L)( confirmed by repeat testing)

3. A previous or new diagnosis of stable CAD according to ICD 10 for at least 6 months, document by following criteria: 1) Stable angina; 2) No AMI or NSTE-ACS within 1 month;and(or) 3) EKG with ischemic ST-segment and(or) T-wave change; and(or)4) coronory artery stenosis ≥50% viewed by coronary CTA or coronary angiography

4. No medication history of clopidogrel/ticagrelor for at least 1 months

5. Female or male, and any race, aged≥18 years, not pregnant.

Exclusion Criteria

1. Blood pressure>160/100 mm Hg;

2. Hypercholesterolemia(LDL-c >240mg/dl);

3. Hemoglobin A1c ≥ 10%;

4. Platelet count less than 10*10^9/L or hemoglobin <10 g/dL;

5. Intolerance or allergy to clopidogrel/ticagrelor or any of the excipients;

6. Patient with known inflammatory conditions or those on anti-inflammatory drug therapy;

7. Second and third degree atrioventricular block;

8. chronic obstructive lung disease or asthma;

9. Creatinine>2 mg/dl;

10. Malignancy;

11. Moderate or severe hepatic impairment;

12. History of intracranial haemorrhage;

13. Active pathological bleeding;

14. Pregnancy or lactation;

15. Any condition that increases the risk for noncompliance or being lost to follow-up;

16. Medicine history of potent CYP3A4 inhibitor(ketoconazole, clarithromycin,etc.);

17. No provision of informed consent.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

AstraZeneca

INDUSTRY

Sponsor Role: collaborator

Tianjin Medical University

OTHER

Sponsor Role: lead

Responsible Party

Xiaofei Wang

Tianjin International Medical Center

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Xiaofei Wang, doctor

Role: PRINCIPAL_INVESTIGATOR

Tianjin First Central Hospital

Locations

Tianjin First Central Hospital

Tianjin, Tianjin Municipality, China

Tianjin First Central Hospital

Tianjin, , China

Countries

China

Facility Contacts

Xiaofei Wang, doctor

Role: primary

wangxiaofei@medmail.com.cn

Other Identifiers

ISSBRIL0241

Identifier Type: -

Identifier Source: org_study_id